Saliva Testing is a Robust Non-Invasive Method for SARS-CoV-2 RNA Detection
Sigitas Palikša 1, Mantvydas Lopeta 1, Jonas Belevičius 1, Vaida Kurmauskaitė 1, Ieva Ašmenavičiūtė 1, Laura Pereckaitė 2, Astra Vitkauskienė 2, Ieva Baliūtytė 3, Monika Valentaitė 3, Auksė Mickienė 3, Julius Gagilas

Saliva sample testing is a robust and reliable non-invasive alternative to the NP swab method for SARS-CoV-2 RNA detection, as well as a promising tool for COVID-19 screening.

Infect Drug Resist. 2021 Jul 27;14:2943-2951. 

A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients
Xue Du 1, Jun Zhang 2, Hongjun Gao 3, Yanhong Tai

"in this study, we analyzed two patients whose ALK statuses
were not consistent using these four methods. We explored the potential reasons for deviation of the test results and found a novel EML4-ALK break site, which had been not described previously."

Thorac Cancer. 2021 Sep 6. 

Palindromic-assisted self-annealing transcription amplification for reliable genotyping of epidermal growth factor receptor exon mutations
Rui Yuan 1, Wanyan Tang 2, Hong Zhang 3, Wenxin You 4, Xiaolin Hu 5, Haiwei Zhang 2, Ling Chen 6, Weiqi Nian 7, Shijia Ding 8, Yang Luo

we propose a palindromic-assisted self-annealing transcription amplification (PASTA) strategy for the reliable detection of circulating EGFR exon mutations.

Biosens Bioelectron. 2021 Dec 15;194:113633. 

Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma and small cell lung cancer via a transcriptomic, biological pathway-based machine learning model
Junhong Guo 1, Likun Hou 1, Wei Zhang 1, Zhengwei Dong 1, Lei Zhang 2, Chunyan Wu

This model was able to give an accurate prediction of LCNEC and SCLC. It may assist clinicians to make the optimal decision for patients with pulmonary neuroendocrine tumors in choosing appropriate treatment.

Transl Oncol. 2021 Sep 14;14(12):101222. 

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer
Yaolin Song 1, Guangqi Li 1, Kun Ju 2, Wenwen Ran 1, Han Zhao 1, Xianglan Liu 1, Mingyu Hou 1, Yulu He 1, Yang Chen 1, Guoliang Zang 3, Xiaoming Xing

"Our study found that MET genomic alterations were statistically related to age and tumor stage and co-existed with mutations of other oncogenic driver genes, such as EGFR and BRAF. Moreover, various splicing site changes at the DNA level led to the
exon 14 skipping mutation at the mRNA level. Further studies are required to clarify the association between MET genomic alterations and prognosis."

Front Oncol. 2021 Sep 30;11:755031.

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
Yalin Xie,1 Ning Su,1 Wei Zhou,2 An Lei,1 Xiang Li,3 Weiwei Li,4 Zhan Huang,4 Wenchang Cen,1 Jinxing Hu5

LUAD patients with concomitant PTB have a poor response to EGFR-TKI treatment, especially in terms of survival outcome.

Cancer Manag Res. 2021 Oct 1;13:7517-7526.